



**ASX ANNOUNCEMENT**  
Wednesday, 19 November 2025

## Results of Annual General Meeting

---

IDT Australia Limited (ASX: IDT) (IDT or the **Company**) advises that, in accordance with Listing Rule 3.13.2 and section 251AA(2) of the Corporations Act, details of the resolutions and the proxies received in respect of each resolution put to the Annual General Meeting of shareholders held today are set out in the attached meeting summary.

Ends.../

Authorised by the Company Secretary of IDT Australia Limited.

For investor and media enquiries, please contact:

Brendon Lau

E: [brendon@vantagepointpartners.com.au](mailto:brendon@vantagepointpartners.com.au)

M: +61 409 341 613

### Forward-looking statements

This announcement contains or may contain forward-looking statements that are based on IDT Australia's beliefs, assumptions, and expectations and on information currently available to IDT Australia.

All statements that address operating performance, events, or developments that IDT Australia or its directors expect or anticipate will occur in the future are forward-looking statements, including, without limitation, statements as to the expectations of IDT Australia or the market it operates in.

IDT Australia believes that these forward-looking statements are reasonable as and when made. You should not place undue reliance on forward-looking statements because they speak only as of the date when made. IDT Australia does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. No assurance or guarantee is, or should be taken to be, given in relation to, and no reliance should be placed on, the future business performance or results of IDT Australia or the likelihood that the current assumptions, estimates or outcomes will be achieved. Actual results, developments or events could differ materially from those disclosed in the forward-looking statements.

#### About IDT

IDT (ASX:IDT) is an Australian pharmaceutical manufacturing company based in Boronia, Victoria, Australia. The Company has extensive experience in the development and production of high potency and high containment pharmaceutical products for local and international clients. IDT's facilities are cGMP compliant and are regularly audited by the US FDA and Australian TGA. With an experienced team of specialists within world-class facilities, IDT provides a full-scale service for new drug development and scale-up, commercial active drug manufacture as well as a variety of oral and injectable finished drug dose forms.

**IDT AUSTRALIA LIMITED**

ANNUAL GENERAL MEETING  
Wednesday, 19 November, 2025

As required by section 251AA(2) of the Corporations Act 2001 (Commonwealth) the following statistics are provided in respect of each resolution on the agenda.

Resolution Voted on at the meeting			Proxy Votes (as at proxy close)				Total votes cast in the poll (where applicable)			
No	Short Description	Strike Y/N/NA	For	Against	Discretionary (OpenVotes)	Abstain	For	Against	Abstain **	Result
1	ADOPTION OF REMUNERATION REPORT	N	188,404,304 86.51%	29,100,269 13.36%	276,414 0.13%	700,111	206,780,718 87.66%	29,109,884 12.34%	930,111	Carried
2	RE-ELECTION OF DIRECTOR DR JANE RYAN	NA	219,543,634 99.56%	650,337 0.29%	311,414 0.14%	330,588	240,082,808 99.73%	650,337 0.27%	330,588	Carried
3	APPROVAL OF INCREASED 7.1A PLACEMENT CAPACITY	NA	218,918,527 99.35%	1,000,066 0.45%	421,414 0.19%	495,966	239,337,701 99.49%	1,230,066 0.51%	495,966	Carried

\*\* - Note that votes relating to a person who abstains on an item are not counted in determining whether or not the required majority of votes were cast for or against that item